Antitumor effect of 6-phenyl-7(6H)-isoselenazolo[4,3-d]pyrimidone on the growth of Ehrlich ascites tumor.
Two selenium compounds have a strong antitumor effect on Ehrlich ascites tumor; 6-phenyl-7(6H)-isoselenazolo[4,3-d]pyrimidone (ISP) especially, markedly inhibited the growth of tumor inoculated i.p. in mice, inducing almost complete regression of tumors at doses of 100 micrograms/mouse per day X 10 with no sign of toxicity. The antitumor activity of 4,5-dihydro-4-methyl-6-oxo-5-phenyl-6H-pyrazolo [4,5-c]isoselenazole(PIS) was weaker than that of ISP. The total lipid and phospholipid contents in the tumor cells treated with ISP were significantly decreased. In addition, the fatty acid pattern of cholesterol esters, phosphatidyl choline and phosphatidyl ethanolamine from the ISP-treated Ehrlich ascites tumor cells differed markedly from that of the corresponding lipids from the control tumor cells.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000032:analysis / Q000473:pathology*; D005227:Fatty Acids / Q000032:analysis; D005260:Female; D008055:Lipids / Q000032:analysis; D051379:Mice; D008813:Mice, Inbred ICR; D009942:Organometallic Compounds; D010743:Phospholipids / Q000032:analysis; D011744:Pyrimidinones / Q000494:pharmacology*; D012643:Selenium / Q000494:pharmacology*
D000970:Antineoplastic Agents; D005227:Fatty Acids; D008055:Lipids; D009942:Organometallic Compounds; D010743:Phospholipids; D011744:Pyrimidinones; C046552:6-phenyl-7(6H)-isoselenazolo(4,3-d)pyrimidone; D012643:Selenium